Thanks for being a decent and more sensible bloke.
I think each to their own, I am holding not for the potential but a lesson for myself and as a reminder to do more research on all stock that I cam across going forward. And this has been working well for me.
Back to the genuine question, I must say the Cfoam at its current stage (I mean as at July 2021), I don't see any viable options at this stage. I would say there might be slight potential there. But really, there is no options/applications:
1) we are heavily relying on Touchstone lab to turn Cfoam into usable final product. we bought all patents from them, but still leasing assets from them and sell them the Cfoam at mate rates.
2) As I mentioned previously, the production has always been bad, I mean the process, not the capacity. Over the years, we have been throwing away nearly millions of Cfoam due to bad quality. So far it has not been fixed it and yet they wanting to boost the production again.
3) The Track record of management and board is really bad.
Lastly, of course it all comes down to your investing style and holding period, if you are here for the potential, then it might be bad for you. If you are here to pick the dips and get out next week, this would be a good stock for a quick profit (also depends on your definition of profit - 1k, 5k or 10k?) At the current volume, it might be easy to get a 5k quick profit easily.
- Forums
- ASX - By Stock
- CFO
- market cap 8mil at 1.4 watch this space !
market cap 8mil at 1.4 watch this space !, page-92
-
- There are more pages in this discussion • 253 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CFO (ASX) to my watchlist
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.468M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
CFO (ASX) Chart |
Day chart unavailable